NCT00775437

Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use

Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg With Active Juvenile Idiopathic Arthritis (JIA)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 2 Years – 4 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study is to evaluate the safety of adalimumab in patients 2 to \< 4 years of age or ≥ 4 years of age weighing \< 15 kg, with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) or polyarticular course JIA.

Conditions

• Juvenile Idiopathic Arthritis

Interventions

Type	Name	Description
DRUG	Adalimumab	Adalimumab solution for injection for subcutaneous use.

Timeline

• Start date: 2009-03-01
• Primary completion: 2013-03-01
• Completion: 2013-03-01
• First posted: 2008-10-20
• Last updated: 2016-01-26
• Results posted: 2016-01-26